Published in Prim Care Companion CNS Disord on March 28, 2013
Why the Diagnosis of Attention Deficit Hyperactivity Disorder Matters. Front Psychiatry (2015) 0.82
Off-label drugs for weight management. Diabetes Metab Syndr Obes (2017) 0.75
A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry (1999) 13.56
The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry (2006) 11.85
Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry (2006) 9.98
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2007) 6.57
Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction (2005) 5.03
Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry (2007) 4.69
Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry (2002) 4.57
Sudden death and use of stimulant medications in youths. Am J Psychiatry (2009) 4.33
Prevalence and treatment of mental disorders among US children in the 2001-2004 NHANES. Pediatrics (2009) 3.98
Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry (1995) 3.98
Treatment of ADHD in children with tics: a randomized controlled trial. Neurology (2002) 3.63
Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry (2008) 3.52
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy (2006) 3.40
Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry (2005) 3.36
Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry (1993) 3.27
ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med (2011) 3.12
Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry (1996) 3.05
Cytogenetic effects in children treated with methylphenidate. Cancer Lett (2005) 3.05
Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry (2008) 2.96
Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry (1999) 2.88
Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics (2003) 2.79
The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse (2004) 2.53
Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry (2005) 2.50
Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry (2006) 2.48
Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder--United States, 2003. MMWR Morb Mortal Wkly Rep (2005) 2.46
Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr (2001) 2.20
National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics (2004) 2.10
ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry (1997) 2.09
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry (2007) 2.03
A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 1.97
Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics (2001) 1.92
A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol (2003) 1.91
Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry (2006) 1.87
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 1.87
Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry (2004) 1.79
Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics (1996) 1.76
Medication use in US youth with mental disorders. JAMA Pediatr (2013) 1.75
The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. Brain (2007) 1.74
Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics (2008) 1.72
Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry (2008) 1.71
Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry (2011) 1.66
Stimulants and sudden death: what is a physician to do? Pediatrics (2006) 1.64
Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr (2006) 1.63
Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2007) 1.56
From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction (2007) 1.54
Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry (1999) 1.53
Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed (2006) 1.51
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol (2005) 1.47
Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol (2008) 1.45
Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry (2008) 1.41
Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res (1989) 1.41
Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord (2000) 1.40
Gender differences in a sample of adults with attention deficit hyperactivity disorder. Psychiatry Res (1994) 1.35
Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health (2003) 1.32
Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev (2006) 1.31
Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2004) 1.30
Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med (2006) 1.26
Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Arch Pediatr Adolesc Med (2008) 1.24
Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry (1996) 1.23
Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics (2009) 1.20
A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol (2004) 1.20
Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics (2009) 1.15
Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord (2001) 1.14
Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord (1995) 1.10
Implications of early versus late onset of attention-deficit/hyperactivity disorder symptoms. J Am Acad Child Adolesc Psychiatry (2000) 1.08
Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology (Berl) (2006) 1.07
Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2008) 1.04
A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2004) 1.03
Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry (1987) 1.01
Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry (2007) 1.00
Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Psychiatry (1982) 0.96
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol (2008) 0.95
Comparative effects of methylphenidate on ADD girls and ADD boys. J Am Acad Child Adolesc Psychiatry (1989) 0.92
The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf (2008) 0.92
Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab (2003) 0.92
Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav (2010) 0.91
Comorbidity in pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am (2009) 0.89
Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry (1999) 0.89
An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs (2008) 0.86
Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol (2004) 0.86
Does pharmacotherapy for attention-deficit/hyperactivity disorder predict risk of later major depression? J Child Adolesc Psychopharmacol (2008) 0.85
Pediatric psychopharmacology update: psychostimulants and tics - past, present and future. J Can Acad Child Adolesc Psychiatry (2006) 0.84
A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2010) 0.83
Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology (1995) 0.82
Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation. J Child Adolesc Psychopharmacol (2010) 0.81
Clinical assessment of psychopharmacological treatment of preschoolers with ADHD. J Clin Exp Neuropsychol (1998) 0.78
Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate. Mutat Res (2009) 0.78
Pharmacologic treatment of pediatric bipolar disorder. Child Adolesc Psychiatr Clin N Am (2009) 0.78
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. Eur J Pharmacol (2007) 0.78
Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics (1999) 0.77
How high a dose of stimulant medication in adult attention deficit hyperactivity disorder? Aust N Z J Psychiatry (2000) 0.77
SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs (2001) 0.77
Is suicidality serious? Curr Drug Saf (2009) 0.76
Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med (2013) 3.76
A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry (2006) 3.68
Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med (2006) 3.57
Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry (2002) 2.37
Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry (2010) 2.31
Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol (2004) 2.30
Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther (2005) 2.08
Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder. Biol Psychiatry (2005) 1.86
Family-based genome-wide association scan of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2010) 1.79
Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr (2005) 1.74
Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry (2007) 1.74
Psychopathology in females with attention-deficit/hyperactivity disorder: a controlled, five-year prospective study. Biol Psychiatry (2006) 1.73
Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry (2011) 1.66
The diagnosis and treatment of Munchausen's syndrome. Gen Hosp Psychiatry (2003) 1.51
Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry (2008) 1.41
The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med (2003) 1.41
Core competencies for fellowship training in psychosomatic medicine: a collaborative effort by the APA Council on Psychosomatic Medicine, the ABPN Psychosomatic Committee, and the Academy of Psychosomatic Medicine. Psychosomatics (2009) 1.39
Central pontine myelinolysis manifested by temporary blindness: a possible complication of lithium toxicity. Ann Clin Psychiatry (2002) 1.38
Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics (2010) 1.33
Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2006) 1.30
Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr (2006) 1.29
The impact of serious mental illness on health and healthcare. Psychosomatics (2010) 1.28
Substance use among ADHD adults: implications of late onset and subthreshold diagnoses. Am J Addict (2007) 1.22
Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics (2009) 1.20
Visual hallucinations: differential diagnosis and treatment. Prim Care Companion J Clin Psychiatry (2009) 1.20
Insertion of foreign bodies (polyembolokoilamania): underpinnings and management strategies. Prim Care Companion CNS Disord (2012) 1.19
A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry (2009) 1.14
Neuropsychological functioning in youth with bipolar disorder. Biol Psychiatry (2005) 1.11
Assessing cannabis use in adolescents and young adults: what do urine screen and parental report tell you? J Child Adolesc Psychopharmacol (2005) 1.09
Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry (2002) 1.05
Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep (2006) 1.04
Falls in the general hospital: association with delirium, advanced age, and specific surgical procedures. Psychosomatics (2009) 1.04
Dread complications of catatonia: a case discussion and review of the literature. Prim Care Companion J Clin Psychiatry (2008) 1.03
Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry (2007) 1.01
Conversion disorder presenting with neurologic and respiratory symptoms. Prim Care Companion J Clin Psychiatry (2005) 1.00
Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry (2009) 1.00
Neuropsychiatric effects of prescription drug abuse. Neuropsychol Rev (2007) 0.99
Linking electronic health record-extracted psychosocial data in real-time to risk of readmission for heart failure. Psychosomatics (2011) 0.99
Psychosocial functioning, familiality, and psychiatric comorbidity in bipolar youth with and without psychotic features. J Clin Psychiatry (2011) 0.96
The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics (2012) 0.95
Genome-wide association study of the child behavior checklist dysregulation profile. J Am Acad Child Adolesc Psychiatry (2011) 0.93
The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families. Nicotine Tob Res (2008) 0.93
Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci (2007) 0.92
Pharmacotherapy of adolescent substance use disorders: a review of the literature. J Child Adolesc Psychopharmacol (2005) 0.91
Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry (2002) 0.91
Successful implementation of an alcohol-withdrawal pathway in a general hospital. Psychosomatics (2008) 0.90
Comorbid pain, depression, and anxiety: multifaceted pathology allows for multifaceted treatment. Harv Rev Psychiatry (2009) 0.90
Prior discharges against medical advice and withdrawal of consent: what they can teach us about patient management. Prim Care Companion CNS Disord (2011) 0.90
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry (2009) 0.90
Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr (2005) 0.90
Depressogenic effects of medications: a review. Dialogues Clin Neurosci (2011) 0.89
An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol (2009) 0.89
The effect of testosterone levels on mood in men: a review. Psychosomatics (2013) 0.88
A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med (2007) 0.88
Psychiatric considerations in the patient receiving organ transplantation: a clinical case conference. Gen Hosp Psychiatry (2004) 0.88
Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature. Prim Care Companion J Clin Psychiatry (2008) 0.88
Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2006) 0.88
Deriving phenotypes for molecular genetic studies of substance use disorders: a family study approach. Drug Alcohol Depend (2006) 0.87
Documentation of decision-making capacity, informed consent, and health care proxies: a study of surrogate consent. Psychosomatics (2011) 0.87
Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr (2005) 0.86
Does exposure to parental substance use disorders increase substance use disorder risk in offspring? A 5-year follow-up study. Am J Addict (2013) 0.86
Temporal association between childhood psychopathology and substance use disorders: findings from a sample of adults with opioid or alcohol dependency. Psychiatry Res (2002) 0.86
Alcohol use during pregnancy: prevalence and impact. Prim Care Companion J Clin Psychiatry (2007) 0.86
Insulin overdose among patients with diabetes: a readily available means of suicide. Prim Care Companion J Clin Psychiatry (2009) 0.86
Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol (2005) 0.85
A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J Biol Psychiatry (2012) 0.85
Neuropsychiatric manifestations of multiple sclerosis. Prim Care Companion J Clin Psychiatry (2008) 0.85
Familial transmission of derived phenotypes for molecular genetic studies of substance use disorders. Drug Alcohol Depend (2007) 0.84
New developments in the treatment of ADHD. J Clin Psychiatry (2006) 0.84
The use of DBT skills in the treatment of difficult patients in the General Hospital. Psychosomatics (2003) 0.84
Staying against advice: refusal to leave the hospital. Prim Care Companion J Clin Psychiatry (2010) 0.83
Current concepts in the validity, diagnosis and treatment of paediatric bipolar disorder. Int J Neuropsychopharmacol (2003) 0.83
Denial of cardiac illness: consequences and management. Prim Care Companion CNS Disord (2011) 0.83
Consultants' conflicts: a case discussion of differences and their resolution. Psychosomatics (2008) 0.83
Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry (2003) 0.83
Complications of carbon monoxide poisoning: a case discussion and review of the literature. Prim Care Companion J Clin Psychiatry (2009) 0.83
Aripiprazole-related tardive dyskinesia. CNS Spectr (2006) 0.83
Demoralization in medical practice. Prim Care Companion J Clin Psychiatry (2007) 0.82
Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine. J Am Acad Child Adolesc Psychiatry (2006) 0.82
Does the medicating ADHD increase or decrease the risk for later substance abuse? Rev Bras Psiquiatr (2003) 0.82
The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep (2014) 0.82
Reasons for substance use among adolescents with bipolar disorder. Am J Addict (2010) 0.82
Family-based association study of the BDNF, COMT and serotonin transporter genes and DSM-IV bipolar-I disorder in children. BMC Psychiatry (2009) 0.81
Impact of executive function deficits in youth with bipolar I disorder: a controlled study. Psychiatry Res (2011) 0.81
Does social class predict substance problems in young adults with ADHD? Am J Addict (2007) 0.81
Medical complications of psychiatric treatment. Crit Care Clin (2008) 0.81
Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation. J Child Adolesc Psychopharmacol (2010) 0.81
Posttraumatic stress disorder and substance use disorder in adolescent bipolar disorder. Bipolar Disord (2009) 0.81
Clinical experience with the management of schizophrenia in the general hospital. Psychosomatics (2003) 0.81
Psychotic symptoms in the elderly. Prim Care Companion J Clin Psychiatry (2005) 0.81
"Playing possum:" differential diagnosis, work-up, and treatment of profound interpersonal withdrawal. Psychosomatics (2011) 0.81
Teaching residents about emotional intelligence and its impact on leadership. Acad Psychiatry (2014) 0.81
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry (2006) 0.80
Reactions to amputation: recognition and treatment. Prim Care Companion J Clin Psychiatry (2007) 0.80
Clinical Challenges to the Delivery of End-of-Life Care. Prim Care Companion J Clin Psychiatry (2006) 0.80
Cocaine and opioid use during pregnancy: prevalence and management. Prim Care Companion J Clin Psychiatry (2008) 0.79